ER+ BREAST CANCER
Clinical trials for ER+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER+ BREAST CANCER trials appear
Sign up with your email to follow new studies for ER+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a certain type of advanced breast cancer (ER+/HER2-). The trial includes 57 participants whose cancer did not respond well to initial treatment. …
Matched conditions: ER+ BREAST CANCER
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New pill targets Cancer's 'Extra DNA' in desperate patients
Disease control OngoingThis early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of cancer-driving genes. The goal is to find a safe dose and see if BBI-355, alone or with other ta…
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a radioactive drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug targets cancer cells that have a protein called SSTR on their surface. The study aims to find t…
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC